Cytokinetics Inc (NASDAQ:CYTK)‘s stock had its “buy” rating reaffirmed by Canaccord Genuity in a research note issued on Thursday, AnalystRatings.Net reports. They currently have a $8.00 price objective on the stock, down from their previous price objective of $9.00. Canaccord Genuity’s price target indicates a potential upside of 92.77% from the company’s current price. A number of other analysts have also recently weighed in on CYTK. Analysts at Needham & Company LLC cut their price target on shares of Cytokinetics from $25.00 to $15.00 in a research note on Monday, April 28th. They now have a “buy” rating on the stock. Separately, analysts at MLV & Co downgraded shares of Cytokinetics from a “buy” rating to a “hold” rating in a research note on Friday, April 25th. Cytokinetics, Inc. (NASDAQ:CYTK) weekly performance is -4.04%. On last trading day company shares ended up $4.28. Analysts mean target price for the company is $11.86. Cytokinetics, Inc. (NASDAQ:CYTK) distance from 50-day simple moving average (SMA50) is -51.24%.
Zalicus Inc. (NASDAQ:ZLCS) a biopharmaceutical company that discovers and develops novel treatments for patients suffering from pain, reported financial results for the first quarter ended March 31, 2014. Zalicus Inc (NASDAQ:ZLCS) shares fell -6.25% in last trading session and ended the day on $0.900. Its return on assets is -98.20%. Zalicus Inc (NASDAQ:ZLCS) quarterly performance is -41.18%.
Genetic Technologies Limited (NASDAQ:GENE) announced it has filed its Quarterly Activities Report for the Quarter ended March 31, 2014 in accordance with the ASX. Total cash receipts from customers during the quarter ended March 31, 2014 were $1.4 million taking the equivalent figure to more than $3.7 million for the nine-month period ended on that date. Genetic Technologies Limited (ADR) (NASDAQ:GENE) shares moved down -3.77% in last trading session and was closed at $1.02, while trading in range of $0.97 – $1.06 -. Genetic Technologies Limited (ADR) (NASDAQ:GENE) year to date (YTD) performance is -28.67%.
Celldex Therapeutics, Inc. (NASDAQ:CLDX) issued a press release announcing its financial results for the first quarter of 2014. Celldex Therapeutics, Inc. (NASDAQ:CLDX) ended the last trading day at $12.79. Company weekly volatility is calculated as 11.49% and price to cash ratio as 3.77. Celldex Therapeutics, Inc. (NASDAQ:CLDX) showed a negative weekly performance of -11.85%.